Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Certara, Inc. (CERT)
Company Research
Source: GlobeNewswire
RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. IGI’s drug candidate is a trispecific T-cell engager (TCE) being studied as a potential cancer treatment. Preclinical research and biosimulation findings were recently published in Nature Cancer. This publication highlighted ISB 2001’s therapeutic potential for relapsed/refractory multiple myeloma patients. Difficulties translating data from animals to patients traditionally limit first-in-human (FIH) dose selection to the most conservative approach. IGI sought to optimize the FIH dose of ISB 2001 to maximize patient safety and efficacy. They turned to Certara to develop an innovative virtual clinical trial platform leveraging their expertise in QSP (quantitative systems pharmacology) and PBPK (physiolo
Show less
Read more
Impact Snapshot
Event Time:
CERT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERT alerts
High impacting Certara, Inc. news events
Weekly update
A roundup of the hottest topics
CERT
News
- Soft Biotech Funding and Cost-Cutting Dragged Certara (CERT) in Q3 [Yahoo! Finance]Yahoo! Finance
- Certara, Inc. (NASDAQ: CERT) had its price target lowered by analysts at Barclays PLC from $14.00 to $12.00. They now have an "equal weight" rating on the stock.MarketBeat
- Certara Inc (CERT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Certara Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Certara, Inc. (NASDAQ: CERT) had its price target lowered by analysts at Robert W. Baird from $18.00 to $13.00. They now have a "neutral" rating on the stock.MarketBeat
CERT
Earnings
- 11/6/24 - Beat
CERT
Sec Filings
- 11/14/24 - Form SC
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- CERT's page on the SEC website